Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453792 | 0.99 | MEN1 (0.49) | MEN1KMT2ABPTFPKMLMNA | |
| SCHEMBL23453822 | 0.93 | MEN1 (0.49) | MEN1KMT2ABPTFPKMLMNA | |
| SCHEMBL23453869 | 0.92 | MEN1 (0.48) | MEN1KMT2ABPTFPKMLMNA | |
| SCHEMBL23453829 | 0.92 | MEN1 (0.51) | MEN1KMT2ABPTFPKMLMNA | |
| SCHEMBL23453836 | 0.91 | MEN1 (0.41) | MEN1KMT2ABPTFPKMLMNA | |
| SCHEMBL23453815 | 0.87 | EPHX2 (0.46) | MEN1KMT2AEPHX2KDM4ETSHR | |
| SCHEMBL23453819 | 0.84 | TP53 (0.42) | MEN1KMT2ABPTFLMNAEPHX2 | |
| SCHEMBL23453876 | 0.79 | EPHX2 (0.39) | MEN1KMT2ALMNAEPHX2ALDH1A1 | |
| SCHEMBL23453803 | 0.79 | SMN1; SMN2 (0.39) | MEN1KMT2APKMLMNAALDH1A1 | |
| SCHEMBL23453838 | 0.79 | ALDH1A1 (0.50) | LMNAEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169804-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2021-06-10 | — | — | US | disclosed |
| WO-2021113365-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169804-A1 | NANOMATERIALS | POLRMT, PHOSPHO1, FABP1 | MEN1 2019/4885KMT2A 2411/4885BPTF 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.